Overview

Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

Status:
Completed
Trial end date:
2018-07-23
Target enrollment:
Participant gender:
Summary
To compare the effects and safety of Anlotinib with placebo in patients with esophageal squamous cell carcinoma(ESCC).
Phase:
Phase 2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd